A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION
Sponsor: Pfizer
This PHASE3 trial investigates Pneumococcal Conjugate Vaccine and Pneumococcal Infections and is currently completed. Pfizer leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Feb 2024 — May 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Jan 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2018 — May 2020 [monthly]
Recruiting PHASE3
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .